Abstract
Recordati's R&D is focused on cardiovascular diseases, anti-infectives,
respiratory, anti-inflammatory, dermatology/gynaecology/urology. This report
provides a full review of the company's activities together with sales
forecasts for key products to 2010.
Recordati was established in 1926 in Milan, Italy and is now listed on the
Italian Stock Exchange. The company employs more than 1,900 people and its
products are sold in about 100 countries.
Recordati markets products in the following fields: Cardiovascular, Central
Nervous System, Gastroenterology/Urology; Respiratory and Anti-infectives. The
company is active in the following areas of research: Cardiovascular; Central
Nervous System, Gastroenterology/Urology and Anti-infectives. However, future
research efforts will focus on fixed combinations in the treatment of
hypertension and the development of therapies for micturition disorders.
Current Growth Drivers
- Zanidip (lercanidipine), an in-house developed calcium channel blocker, is
Recordati's top selling product by a considerable margin, accounting for
around 15 per cent of the company's total revenue. The product continues to
sell well, and Recordati is investing in new combinations and formulations
which should ensure future success and growth.
- Peptazol (pantoprazole), a proton pump inhibitor for the treatment of
ulcers and gastro-oesophageal reflux disease, has demonstrated good
year-on-year growth since its 2002 launch in the Italian market.
Key Late-Phase Products Reaching the Market Place
- Zanipress (lercanidipine+enalapril) is a new fixed combination treatment
for hypertension developed by Recordati. It is currently awaiting approval in
Germany, which will act as the reference member state for approval in the rest
of Europe. Its launch will support the sales of Zanidip and aid Recordati in
making further gains in the European hypertension market.
- Fentanyl is a centrally acting, potent analgesic which is being developed
as a transdermal patch for the treatment of moderate to severe pin. Recordati
has acquired rights to market this product in all the major European markets
and the company hopes its launch will expand its analgesic product portfolio.
View Cart
